ONO-5334

08/01/2014 - "The results of this study suggest that ONO-5334 has good therapeutic potential for the treatment of osteoporosis."
07/01/2019 - "Since these results support a different mode of action for ONO-5334 compared with that of ALN, ONO-5334 may offer new therapeutic options to patients with osteoporosis."
06/01/2011 - "With a significant increase in BMD, ONO-5334 also demonstrated a new mode of action as a potential agent for treating osteoporosis. "
01/01/2011 - "ONO-5334 has been shown to prevent the decrease in bone mineral density (BMD) in the ovariectomized cynomolgus monkey osteoporosis model. "
08/01/2014 - "ONO-5334, a selective inhibitor of cathepsin K, is a potential new treatment for osteoporosis. "

06/01/2011 - "The objective of the study was to investigate the efficacy and safety of ONO-5334 in postmenopausal osteoporosis. "
06/01/2011 - "Safety and efficacy of the cathepsin K inhibitor ONO-5334 in postmenopausal osteoporosis: the OCEAN study."
06/19/2017 - "ONO-5334 is a cathepsin K inhibitor that induced bone mineral density (BMD) gain in a phase II study in postmenopausal osteoporosis patients. "
06/19/2017 - "Antiresorptive effect of a cathepsin K inhibitor ONO-5334 and its relationship to BMD increase in a phase II trial for postmenopausal osteoporosis."
03/01/2014 - "The effect of the cathepsin K inhibitor ONO-5334 on trabecular and cortical bone in postmenopausal osteoporosis: the OCEAN study."

12/01/2011 - "These findings indicate that ONO-5334 is a specific inhibitor for cathepsin K and thus may be a novel therapeutic agent for metabolic bone diseases."
01/01/2011 - "In a 12-month clinical study with postmenopausal osteopenia or osteoporosis, ONO-5334 showed a significant increase in BMD compared with placebo and a similar magnitude of suppression on bone resorption compared with the current well known anti-resorptive agents, bisphosphonates, but with little or no suppression on bone formation. "

01/01/2019 - "Concomitant use of ONO-5334 with MTX reduced architectural joint destruction compared to MTX alone; therefore, ONO-5334 may help to prevent joint destruction in combination with MTX for the treatment of rheumatoid arthritis."

08/01/2014 - "The simulation results showed that ONO-5334 SRT should provide comparable BMD responses at a lower dose relative to IRT (a finding consistent with the results from a previous population PK-PD modeling study with bone resorption markers). "
01/01/2014 - "Plasma concentrations of ONO-5334 and bone resorption markers were thoroughly evaluated in those studies. "
01/01/2016 - "Morning administration of ONO-5334 showed a more consistent suppressive effect on bone resorption than evening administration. "
01/01/2014 - "Based on the developed model, serum CTX and NTX after administration of ONO-5334 IRT or SRT were simulated, and the results showed that ONO-5334 SRT would provide comparable PD effect on bone resorption markers with lower dose relative to IRT. "
01/01/2014 - "An indirect response model described relationships between bone resorption markers and plasma concentrations of ONO-5334. "